RecruitingPhase 2NCT05096390
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
Studying Papillary renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Leon Berard
- Principal Investigator
- Sylvie NEGRIER, PhDCentre Leon Berard
- Intervention
- Axitinib Oral Tablet [Inlyta](drug)
- Enrollment
- 72 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (12)
- Ico - Paul Papin, Angers, France
- CHU de BESANCON, Besançon, France
- Chu Bordeaux, Bordeaux, France
- Centre Jean Perrin, Clermont-Ferrand, France
- Centre Leon Berard, Lyon, France
- Institut Paoli-Calmettes, Marseille, France
- Centre Antoine Lacassagne, Nice, France
- Ap-Hp Hôpital Europeen Georges Pompidou, Paris, France
- Ico-Rene Gauducheau, Saint-Herblain, France
- Iuct-Oncopole Institut Claudius Regaud, Toulouse, France
- Institut de Cancerologie de Lorraine - Alexis Vautrin, Vandœuvre-lès-Nancy, France
- Gustave Roussy, Villejuif, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05096390 on ClinicalTrials.govOther trials for Papillary renal cell carcinoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT05411081Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE3NCT05043090Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCCAstraZeneca